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Central arterial stiffness, indicated by pulse wave velocity (PWV), is increased during the 
hour post ultramarathon (ULT), but it’s currently unknown if PWV remains elevated 24 
hours after ULT or marathon (MAR). PURPOSE: To determine the effects of ULT and 
MAR on C-reactive protein (CRP), aortic blood pressure (BP), aortic augmentation index 
(AIx), PWV, and LF:HF ratio. We hypothesized that CRP, AIx, PWV and LF:HF ratio 
would be elevated 24 hours post-race. Our secondary hypothesis was that changes in 
PWV would be inversely correlated to the percentage of moderate activity (3-6 METs) 
during competition. METHODS: Applanation tonometry was used to measure aortic BP, 
AIx and PWV in 12 endurance athletes (36±2 yr) approximately 18 hours before and 24 
hours after an ULT or MAR. Plasma CRP, resting BP, and LF:HF ratio were also 
measured. Intensity and pacing were quantified via wrist accelerometry. RESULTS: In 
relation to baseline vs. 24 hour post-race, respectively, CRP was significantly (p<0.05) 
elevated (0.5±0.1 vs. 7.0±1.0 mg/L), while resting aortic systolic BP (111±3 vs. 101±3 
mmHg) and aortic diastolic BP (73±3 vs. 64±3 mmHg) were significantly lower. PWV 
and LF:HF ratio were similar 24 hours post-race compared to baseline, while AIx was 
lower (p=0.05) post-race (13±4 vs. 6±3%). Finally, changes in PWV from pre- to post-
race were inversely correlated (r=-0.60) to the percentage of moderate activity. 
CONCLUSION: CRP was increased 24 hours post-race, while at the same time aortic 
BP was decreased. Reduced AIx may contribute to the acute exercise-induced 
hypotension in long-distance runners 24 hours post-race. Results from our secondary 
hypothesis indicated that long-distance runners may have better PWV outcomes by 
pacing with intermittent moderate intensity (i.e., jogging or walking). 
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CHAPTER I – To be submitted to Medicine & Science in Sports & Exercise 




 Paragraph 1 Participation in marathon and ultramarathon running events has 
been on the rise in recent years (18, 51). Despite the increased participation, the acute 
responses to these long-distance running events are not completely understood. For 
example, it is presently unclear if long-distance running participants are at an elevated 
cardiovascular risk or whether they are in a cardioprotective state the day after an event. 
Examining blood pressures, vascular function, and systemic inflammation before and 
after such events can help provide important insight into a person’s health when 
competing in these popular running events. 
  Paragraph 2 Routine aerobic exercise is reported to reduce measures of arterial 
stiffness (39, 47, 48) and to induce post-exercise hypotension (PEH) (7, 29, 40, 41). 
Recent evidence demonstrated measures of central arterial stiffness were increased within 
the first hour following an ultramarathon (4), but it is unknown if these measures remain 
changed 24 hours post-race. Ultra distance triathlons are reported to result in increased 
sympathetic activation (11), indicated indirectly by the low-frequency to high-frequency 
(LF:HF) ratio determined from heart rate variability (HRV). In regard to systemic 
inflammation, C-reactive protein (CRP) is reported to not be elevated immediately post 
marathon (51, 52), but is elevated immediately after 24-hr (51) and 200 km (25) 
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ultramarathons and also 24 hours after a marathon (52). Finally, it is unclear if varying 
intensities may influence acute cardiovascular or inflammatory outcomes. 
 Paragraph 3 The purpose of this study was to determine how ultramarathon 
events influenced cardiovascular responses. Our primary hypothesis was that CRP, pulse 
wave velocity (PWV), aortic augmentation index (AIx), and LF:HF ratio would be 
elevated 24 hours post-race. Our secondary hypothesis was that intermittent bouts of 
moderate intensity, quantified as a higher percentage of race time between 3 and 6 METs 
via wrist accelerometry, would result in lower measures of central arterial stiffness (i.e 
PWV).   
 
METHODS 
 Paragraph 4 Subjects. Data is reported as mean ± SE. Twelve healthy endurance 
athletes (8 men and 4 women, n = 12), age 36±2 yr with a body mass index (BMI) of 
22±1 kg/m
2
, volunteered to participate in this study. Participant characteristics and pre- 
and post-testing times are shown in Table 1. All volunteers had significant marathon 
and/or ultramarathon experience. Testing was performed before and after either the 
Marquette Trail 50 (80 km trail race, n=5; 50 km trail race, n= 3) or Marquette Marathon 
(42 km road race, n=4) races held in Marquette, MI. All participants were non-smokers, 
free of cardiovascular disease, and not currently taking any type of medications. They 
abstained from exercise, caffeine, and alcohol for at least 12 hours before baseline 
testing. Additionally, all participants fasted for at least 3 hours prior to visiting the lab. 
Runners provided their written informed consent and all study procedures were approved 
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by the Institutional Review Boards at Northern Michigan University and Michigan 
Technological University. 
 Paragraph 5 Study design. All data collection was performed in the Exercise 
Science Laboratory at Northern Michigan University. First, anthropometric data such as 
height, weight and body fat were measured. Second, a 50 µL finger poke blood sample 
was obtained for CRP concentration. Third, the participant rested in a supine position for 
at least 5 minutes while ECG electrodes and tonometry pulse sites were marked, and then 
for an additional 5 minutes before any recording. Fourth, heart rate variability was 
recorded for 5 minutes during supine rest. Fifth, brachial artery blood pressures were 
measured in triplicate and averaged. Finally, pulse wave analysis was performed at the 
radial artery near the right hand to obtain two quality recordings. This was immediately 
followed by performing central pulse wave velocity measurements in duplicate at the 
carotid and femoral pulse sites. 
 Paragraph 6 Anthropometrics. Height was measured to the nearest cm with a 
standard stadiometer, while weight and body fat were recorded with a bioimpedance 
scale (Tanita BC-418). Body mass index was determined from the height and weight 
measurements above. 
 Paragraph 7 Heart rate variability. Following at least 10 minutes of supine rest, 
HRV recordings were performed for 5 minutes in a quiet supine position. These 
recordings utilized a standard 3-lead surface electrode configuration and a SphygmoCor 
system (CPVH, AtCor Medical, Sydney, Australia). The LF:HF ratio was determined and 
used as a general indicator of sympathetic vs. parasympathetic activation. 
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 Paragraph 8 Blood pressures and pulse wave analysis. Brachial blood 
pressures were taken in triplicate after at least 15 minutes of supine rest with an 
automated cuff (Omron HEM-907XL, Omron Health Care, Vernon Hills, IL) with at 
least 1 minute between each recording. We reported the averages of these three readings 
(Table 1) and also used the average systolic arterial pressure (SAP) and diastolic arterial 
pressure (DAP) to calibrate the SphygmoCor system. Pulse wave analysis was performed 
in a resting supine position by recording pressure waveforms from the radial artery on the 
right wrist using a small pressure transducer (Millar Instruments, Houston, TX) in 
conjunction with the SphygmoCor CPVH system. Pulse wave analysis recordings were 
completed in duplicate with an operator index of ≥ 80.  
 Paragraph 9 Pulse wave velocity. Central arterial stiffness was estimated from 
pulse wave velocity recordings that were obtained in duplicate from the right femoral and 
right common carotid artery. Proximal distance was calculated in mm from the 
suprasternal notch to the right common carotid site, and the distal distance was calculated 
in mm from the suprasternal notch to the right femoral artery. Next, pulse wave velocity 
was estimated from the foot of the pressure waveforms from the carotid and femoral sites 
(10 cardiac cycles at each site x 2 measurements at each site). The pressure waveforms 
were gated to the 3-lead ECG recordings as described by the manufacturer.  
 Paragraph 10 Accelerometry. Each participant was equipped with an Actical 
accelerometer (Respironics, Inc.) during baseline testing. It was worn on the wrist 
throughout racing and until post-race follow-up testing. Accelerometer data was 
downloaded and summarized according to manufacturer guidelines with markers placed 
at the start and end of the race. This data was summarized as moderate intensity exercise 
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between 3 and 6 METs and vigorous intensity exercise as greater than 6 METs. The 
percentages of race time at moderate and vigorous intensity were used for correlation 
analyses.  
 Paragraph 11 Data analysis. Height was reported to the closest 0.1 cm, weight to 
the nearest 0.1 kg, and body fat to the nearest 0.1%. LF:HF ratio or HRV was reported as 
a 5 min average while starting after at least 10 minutes of supine rest. Resting brachial 
blood pressures and resting heart rates were presented as the average of 3 supine 
recordings, with 1 min between each measurement, after at least 15 minutes resting 
supine. Brachial blood pressures were reported as SAP, DAP, mean arterial blood 
pressure (MAP), and pulse pressure (PP). Finally, pulse wave analysis and pulse wave 
velocity were recorded in a supine position following at least 20 minutes supine rest. 
From the pulse wave analysis recordings we reported aortic systolic arterial pressure 
(aSAP), aortic diastolic arterial pressure (aDAP), aortic mean arterial pressure (aMAP) 
and aortic pulse pressure (aPP). We also reported aortic augmentation index (AIx) from 
the radial pressure waveform recordings. Pulse wave velocity (PWV) was calculated 
from the average of two consecutive recordings from the carotid and femoral sites. 
 Paragraph 12 Statistical analyses. Repeated measures analysis of variance was 
utilized to compare major variables such as CRP, blood pressures, LF:HF ratio, AIx, and 
PWV from pre vs. post (condition x 2) all entered as within subjects factors with race 
distance entered as a between-subjects factor (i.e., 42 km 50 km and 80 km). No 
condition x distance interactions were detected (P > 0.05 for all), thus major variables 
were compared using 2-tailed paired t-tests. All P-values reported represent results from 




 Paragraph 13 Per Table 1, our results indicated body mass, SAP, DAP, and MAP 
were significantly decreased 24 hours post-race when compared to baseline values. In 
contrast, resting HR and HRV (LF:HF ratio) were similar when comparing the pre-race 
baseline values to 24 hour post-race values. General systemic inflammation was 
significantly (P < 0.01) increased from pre- to post-race as indicated by changes (i.e., 
elevated) in CRP, shown in Figure 1. 
 Paragraph 14 Comparisons of pre-race baseline and 24 hour post-race aortic 
blood pressures are shown in Figure 2. Figure 3 demonstrates that while PWV was 
unchanged, AIx was significantly (P = 0.05) reduced 24 hours post-race. Even though 
mean PWV was unchanged, changes (Δ) or fluctuations in PWV were observed and  
associated with percentage of race time at a specific intensity. Figure 4a demonstrates 
that ΔPWV was inversely correlated with the percent of race time performing moderate 
activity, while Figure 4b shows that ΔPWV was directly correlated with the percentage of 
race time performing vigorous activity.   
 
DISCUSSION 
 Paragraph 15 This study is the first to examine inflammation, blood pressure, 
wave reflection, and sympathetic vs. parasympathetic tone 24 hours after a long-distance 
running event. We present one confirmatory and four new findings. Results of the present 
study confirmed that CRP is significantly elevated 24 hours after a long-distance running 
event. In addition, there are 4 novel findings: 1) brachial blood pressure is reduced 24 
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hours post-race, 2) aortic blood pressure is reduced 24 hours post-race, 3) AIx is reduced 
24 hours post-race, and 4) PWV, heart rate and HRV were similar to pre-race values 24 
hours post-race. Finally, our correlation data suggested that central arterial stiffness (i.e., 
PWV) may be lower 24 hours post-race when a participant performs intermittent 
moderate intensity bouts throughout the race even though these fluctuations may be 
incidental to stopping and starting, such as around an aid station. 
 Paragraph 16 Two previous studies indicated that CRP was not elevated 
immediately after a marathon (51, 52), but became elevated 24 hours post-marathon (52) 
and at 12 hours and 24 hours of a 24 hour race (51). One other ultramarathon study 
reported a 3 fold increase in CRP after 100 km and 23 fold increase after 200 km (25). 
CRP was significantly elevated 24 hours post-race which was consistent with the findings 
of previous studies. Elevated CRP is reported to potentially stiffen arterial walls and 
prevent vasodilation (27) which may contribute to increases in blood pressure. Likewise 
one recent study reported simultaneous increases in peripheral arterial stiffness and CRP 
following a 3.5 day military drill that required participants to travel 135 km on foot (23).  
However, one previous study, after short duration maximal exercise, reported an inverse 
relationship between systolic arterial blood pressure and baseline CRP (7). Thus the 
effect of increased CRP post-race on PEH and arterial stiffness remains unclear. Results 
of our study are in contrast to Kampus et al. (23), as CRP was elevated 24 hours post-
race, while brachial and central PEH persisted along with AIx being reduced. Our results 
are in agreement with a previous study where genetically induced increases in CRP did 
not result in an elevated risk for ischemic vascular disease (54). 
8 
 
 Paragraph 17 One previous ultramarathon study has demonstrated brachial PEH 
5 minutes post-race (19) while other studies have reported brachial PEH up to 60 minutes 
post-race (4, 42). One of the aforementioned studies indicated that central arterial 
stiffness is increased within the first hour post-race (4), while another similar study 
reported that peripheral arterial stiffness was decreased at the same time (42). Results of 
the current study reveal that brachial and aortic PEH persist for 24 hours post-race. The 
duration of this PEH may be related to the duration and intensity during the long-distance 
running events (29, 40, 41). Although central arterial stiffness was unchanged 24 hours 
post-race in the present study, AIx was significantly reduced. It is possible that the 
reduction of AIx contributeed to PEH 24 hours after a long-distance running competition. 
 Paragraph 18 One previous study indicated an increased LF:HF ratio 24 hours 
after an Ironman triathlon (11), which represented an increase in sympathetic activation. 
Our results are in contrast to Gratze et al. (11), as the LF:HF ratio was unchanged by 
marathon or ultramarathon participation in the present study. The lack of change in 
LF:HF ratio in the current study may be due to the marathon or ultramarathon in the 
present investigation inducing a lower ‘dose’ of training. One previous study indicated 
that changes in LF:HF ratio are dose dependent (31). 
 Paragraph 19 One recognized limitation in the present study was the relatively 
small number of participants. We coordinated recruitment with the race director for the 
Marquette Trail 50 race for several weeks in advance, but it was difficult to coordinate 
participation. Many participants traveled from a long distance, while others did not meet 
all of the study inclusion criteria. Because of the small number of participants in the 
ultramarathon, we examined 4 participants before and after the Marquette Marathon. We 
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do not view this as a major limitation because we did not detect any interactions of 
distance on our primary independent variables (i.e., blood pressure, AIx, and CRP). 
 Paragraph 20 In summary, we determined that CRP was elevated 24 hours post 
long-distance running race, while at the same time brachial and aortic PEH persisted. At 
the same time point, AIx was significantly reduced which may contribute to the PEH 
observed. Heart rate, LF:HF ratio, and central PWV were not different than pre-race 
values at 24 hours post-race. Finally, the percentage of moderate intensity activity during 
the race appears to result in more favorable central PWV responses as demonstrated by 
the significant inverse correlation. In conclusion, metabolic inflammatory markers are 
increased 24 hours post-race, but brachial blood pressure, central blood pressure, and AIx 
were all significantly reduced one day after a long-distance running event.     
 Paragraph 21 Acknowledgements. This project was funded by an Excellence in 
Education Research Grant from Northern Michigan University to Bridget Durocher. The 
coauthors of the manuscript to be submitted to Medicine and Science in Sports and 
Exercise will include: Scott N. Drum, Phillip B. Watts, Marguerite T. Moore, Morton H. 
Harwood, John J. Durocher. We appreciate our volunteer participants and research 




Table 1. Participant testing time, weight, brachial blood pressures and heart rate. 
Variable Pre-Race Post-Race P-value 
Testing time (hrs) 18±3 24±1 = 0.061 
Weight (kg) 65±3 65±3 = 0.046 
SAP (mmHg) 129±4 121±4 = 0.001 
DAP (mmHg) 73±3 65±3 = 0.003 
MAP (mmHg) 92±3 83±3 = 0.001 
HR (beats/min) 55±3 56±3 = 0.773 
HRV (LF:HF ratio) 2±1 1±0 = 0.304 
SAP, systolic arterial blood pressure; DAP, diastolic arterial blood pressure; MAP, mean 








Figure 1. Plasma concentration of C-reactive protein (CRP) is shown for pre- and post-
race. Plasma CRP was significantly higher post-race than pre-race. *P < 0.01. 
 
Figure 2. Aortic blood pressures are shown for pre- and post-race. Aortic systolic arterial 
pressure (aSAP), aortic diastolic arterial pressure (aDAP), and aortic mean arterial 
pressure (aMAP) were all significantly lower post-race, while aortic pulse pressure (aPP) 
was similar at pre- and post-race. *P < 0.01. 
 
 Figure 3. Measures of arterial stiffness are shown for pre- and post-race. Central pulse 
wave velocity (PWV; on the left) was similar at pre- and post-race, but aortic 
augmentation index (AIx; on the right) was significantly lower post-race. *P = 0.05. 
 
Figure 4. Changes (Δ) in PWV versus the percentage of race time performing moderate 
activity (i.e. 3 to 6 METs) was inversely correlated as shown on the top. The bottom 
shows that ΔPWV was directly correlated to the percentage of race time performing 














































































Figure 3.  


























































































Moderate Activity (%) 
r = 0.609 
r = -0.596 
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CHAPTER II – LITERATURE REVIEW 
 
Overview of Distance Running 
 Ultramarathon running has grown in popularity since the first premier 100 mile 
running event in 1977 (18). That particular ultramarathon event reported 14 participants 
and 3 finishers, and currently there are 400 awarded slots for the race and about 300 
finishers (18). An ultramarathon is classified as any running event over 26.2 miles 
(42km) (33). Some of the most common lengths in the United States are 50 km, 50 miles, 
100 miles, timed 24 and 48 hour events, and multi-day events. Many of these races travel 
over mountainous terrain somewhat similar to the local Marquette Trail 50 (Marquette, 
MI) that is held annually in August.   
 
Physiological Characteristics 
 The most common age range of ultramarathon participants is 40-44 years old (18) 
and the average body mass index (BMI) is 22-24 (kg/m
2
) (26, 42). Knetchle et al. (26) 
report most ultramarathon runners train 11±6 hours/week during training. The percentage 
of male and female ultramarathon participants is not entirely clear, but one recent 
ultramarathon study included about 33% females (42). Ultra-endurance runners tend to 
have a high percentage of type I muscle fibers which aid in their ability to utilize aerobic 
metabolism and to prevent fatigue (34, 35). Well developed, but flexible, muscles of the 
lower body such as those of the quadriceps, hamstrings, and calves are also important to 
ultra-runners (35). The upper body, especially the upper limbs, should be slender and less 
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developed to improve performance (26). Finally, several other performance 
characteristics may be important to ultra-endurance runners, such as relative VO2max, 
lactate threshold (LT), and running velocity at LT (51). 
 
Impact of Regular Aerobic Exercise on Metabolic and Cardiovascular Health 
Regular aerobic endurance exercise has numerous health benefits such as 
reducing: resting blood pressure (12), body fat (53), general inflammation (2), 
sympathetic autonomic tone (21), and arterial stiffness (21, 48). However excessive doses 
of aerobic exercise may potentially be harmful on these same measures of health. It is 
currently unclear how marathon running or ultra-marathon running impact cardiovascular 
health in regard to the relationship between inflammation (i.e., C-reactive protein) and 
arterial stiffness. Additionally, there is no evidence of how pacing strategies might impact 
short-term cardiovascular health. For instance, is acute cardiovascular health impacted 
negatively if someone has an undulating pace versus someone who runs at a steady pace 
throughout the race? Previous studies have shown that the arterial stiffness of marathon 
runners is higher than those of age matched physically active control groups (32). Yet the 
lower intensity and longer duration of ultramarathon runners have been controversial in 
this area. Therefore, the goal of the present review is to investigate how an extreme dose 
of aerobic exercise such as an ultramarathon influence traditional (i.e. CRP and brachial 
blood pressure) and non-traditional (i.e., arterial stiffness, aortic blood pressure and 




C - Reactive Protein and Long-Distance Running 
 CRP is an acute phase protein that is an indicator of acute, general inflammation. 
Micro damage to the skeletal muscle created by exercise can induce and inflammatory 
response. This inflammation in conjunction with glycogen depletion can signal the 
production of cytokines, such as interleukin-6 (IL-6), which stimulates the liver to 
increase production of CRP (24). Excess plasma concentration of CRP may play a direct 
role in the development of atherosclerosis (51), and is associated with increases in 
endothelium stiffness and poor vasodilation (27). In addition, increases in CRP appear to 
be associated with increased sympathetic and decreased parasympathetic activation (14). 
Based on previous studies CRP appears to have a multifactorial influence on increasing 
cardiovascular risk. 
 A standard aerobic endurance exercise program can help reduce inflammatory 
markers such as C-reactive protein (46), but more extreme bouts of aerobic exercise such 
as a mountain marathon (52) or ultramarathon (25, 51) can lead to significant increases in 
plasma CRP. While CRP is not increased immediately at marathon distance (51, 52), it is 
greatly increased at 24 hours post marathon (51) and by 12 hours and 24 hours of a 24-hr 
race (51). Another study reports that CRP is significantly increased at 100 km and 200 
km of a 200 km race (25). Wilhelm et al. (52) determined that CRP returned to baseline 
within 5 days after a mountain marathon, but they did not test between days 1 and 5 after 
the race. Another study by Irving et al. (20) specifies that CRP remained elevated for 3 
days following a 56 km running race. Thus, it appears that ultramarathons induce a 
significant inflammatory response that persists for at least 3 days. It is possible that the 
extent of increased CRP following an ultramarathon is related to the eccentric muscle 
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contractions required when running downhill. One recent study reports that muscle 
damage and exercise-induced arterial stiffness appears to be related to eccentric 
contractions during downhill running (6).   
 
Heart Rate Variability and Ultra-Endurance 
 Heart rate variability, or spontaneous changes in the R-R interval on an 
electrocardiogram, can be used to indicate sympathetic vs. parasympathetic autonomic 
nervous system tone. The frequency of changes in the R-R interval are specifically useful 
when converted from the time domain to the frequency domain with Fourier transform 
algorithm, with low frequency (LF) primarily representing sympathetic activation and 
high frequency (HF) indicating parasympathetic activation (30, 37). The LF: HF is often 
utilized to indicate the balance between sympathetic and parasympathetic activation, with 
an increase in the ratio indicating increased sympathetic autonomic tone (9, 22, 37).  
Aerobic endurance training generally leads to a decrease in the LF: HF ratio; 
however, a recent study indicated that this response was dose-dependent and followed a 
U-shaped curve (31). In fact, another study by Gratze et al. (11) determined that 
sympathetic activation is increased (indicated by an increase in the LF:HF ratio) 
following an Ironman Triathlon, and that the LF:HF ratio remains elevated for at least 24 
hours post-race. Therefore, it is likely that high-dose endurance events such as marathon 
or ultramarathon would also lead to increased sympathetic activation. Increased 
sympathetic activation, indirectly indicated by elevated LF:HF ratio, is associated with 




Blood Pressure and Ultramarathon Running 
 Two previous articles summarize the influence of aerobic endurance exercise on 
blood pressure and report significant post-exercise hypotension (PEH) within the hour 
following most aerobic exercise bouts (29, 40). The extent and duration of PEH appears 
to be influenced by intensity (7, 41) and increases in exercise duration up to 90 minutes 
(40). One early study on ultramarathon runners indicated that PEH was present 5 minutes 
after an 80 km running event (19). Two more recent studies on ultramarathoners indicate 
that PEH persists for at least 40 to 60 minutes after a 120 km or 195 km event (4, 42). It 
is presently unclear if PEH persists into the next day following completion of an 
ultramarathon running event. It is likely that PEH may persist for at least 24 hours, as one 
early case-study reported significant PEH for up to 4 to 10 hours after jogging (8). If PEH 
lasts into the next day following an ultramarathon, perhaps this could induce a significant 
cardioprotective effect (40). 
  Potential mechanisms for PEH include may include factors that reduce cardiac 
output (heart rate x stroke volume) and / or reductions in total peripheral resistance (TPR) 
(the overall resistance to blood flow in systemic vessels). Changes in TPR are mostly due 
to changes in the diameter of blood vessels (40). The specific mechanisms for PEH 
include reduced TPR (40), reduced HR (10), or reductions in plasma volume that could 
reduce stroke volume (19, 20). The primary mechanism for PEH appears to be the 
reduction in TPR through either a reduction in sympathetic activation and / or release of 




Central Blood Pressure and Arterial Stiffness 
 Normal aortic blood pressure (45) and reduction in reflected waves back towards 
the heart during systole are extremely important factors for cardiovascular health (3, 38). 
To perform aortic wave reflection analysis, a small surface tonometer is utilized to record 
a forward traveling wave generated during ventricular systole and to estimate reflected 
waves from the peripheral circulation, mostly from small vessels such as arterioles (38). 
The most important aortic wave reflection characteristic is the aortic augmentation index 
(AIx).  AIx is used to non-invasively estimate systemic arterial stiffness and is calculated 
as: [peak aortic systolic pressure - inflection point of the reflected pressure wave] / [peak 
aortic systolic pressure - minimum aortic diastolic pressure] as shown below in Figure 5 
(38). Nichols et al. (38) defined central arterial stiffness to be a key indicator of 
cardiovascular health. The central arterial pressure is derived from a forward travelling 
pulse wave that travels down the artery to the peripheral arterioles, or until it hits an area 
too stiff to continue. The wave from the periphery is then projected back to the central 
aorta. If the wave reflects back before the end of systole the augmentation index is then 
elevated, indicating aerial stiffness is increased and there is an elevated risk of 
cardiovascular disease (3, 38). 
 Although AIx is a strong indicator of vascular health by measuring aortic wave 
reflection and providing a general indicator of arterial stiffness (3, 38, 45), assessment of 
central (i.e. carotid to femoral) pulse wave velocity (PWV) is reported to be the ‘gold 
standard’ assessment for arterial stiffness (13). The pulse wave analysis technique is a 
desired method to AIx and trusted estimates of aortic blood pressures, while PWV is 
preferred for the most accurate assessments of arterial stiffness (13). 
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   Arterial stiffness, as indicated by AIx, can fluctuate based on levels of estradiol in 
female participants. For instance, AIx is lowest during the late follicular phase of the 
menstrual cycle when estradiol is highest (1). Absence of the menstrual cycle, or 
amenorrhea, may also lead to poor vascular function due to low levels of estradiol (15, 
28). Two recent studies have shown that supplementation with folic acid can improve 
endothelial function in amenorrheic athletes (16, 17). Therefore when assessing AIx and 
other wave reflection measures, controlling for the potential confounding effect of female 
sex hormones is advisable. 
 Numerous studies have indicated an association between increased physical 
activity / aerobic exercise and reduced arterial stiffness (39, 47, 48). Aerobic exercise can 
effectively decrease arterial stiffness in those that appear healthy (48) or clinical 
populations such as obese individuals (36). More recent studies have indicated that 
training for marathons (49) and ultramarathons (5, 43) does not appear to heighten aortic 
blood pressure or arterial stiffness. Two recent studies following ultramarathon indicate 
that central arterial stiffness is increased (4), but peripheral arterial stiffness is decreased 
(42) during the first hour post-race. It is somewhat unclear if measures of arterial stiffness 
are correlated to inflammatory markers post-ultramarathon, but a study on military cadets 
traveling 135 km over 3.5 days suggests that long distance exercise-induced increases in 
CRP may contribute to increased peripheral arterial stiffness (23). 
 
Potential Role of Intensity Varations on Arterial Stiffness 
 It appears that reductions in arterial stiffness may depend on significant intensity 
(44) and duration (50). Some recent evidence suggests that intermittent exercise may be 
23 
 
more advantageous than continuous exercise for helping to induce the vascular 
adaptations necessary to reduce arterial stiffness. (50). While intermittent short-duration 
cycling exercise appears to induce a more favorable acute response in arterial stiffness 
(50), the influence of varying intensities on measures of arterial stiffness following an 
ultramarathon remain unknown. 
 
Summary 
 Long-distance running events like ultramarathons or marathons appear to increase 
systemic inflammation, which is often quantified as plasma concentration of CRP. Long-
distance running events appear to induce significant PEH for at least 1 hour post-event, 
but it is unclear how long PEH persists. It is likely that aortic blood pressure is also 
reduced post long-distance running event, but it is unclear how long aortic PEH may 
persist. Based on Ironman triathlon data, it appears that sympathetic activation, indicated 
by an increase in the LF:HF ratio, would be increased for at least 24 hours post-
ultramarathon. Finally, previous literature demonstrates central arterial stiffness is 
increased during the first hour post-ultramarathon, while peripheral arterial stiffness is 
decreased at the same time. However, it appears that peripheral arterial stiffness may 











CHAPTER III – CONCLUSIONS AND RECOMMENDATIONS 
 
Conclusions 
 The present study had one verified one previous finding and presents four novel 
findings. Results of the present work confirm that long-distance running (i.e. 
ultramarathon or marathon) induces a significant elevation in plasma CRP that persists 
for at least 24 hours post-event. In addition, there are four new findings from the present 
study: 1) brachial PEH persists for at least 24 hours post-race, 2) aortic PEH persists for 
at least 24 hours post-race, 3) AIx is reduced at 24 hours post-race, and 4) 24 hour post-
race PWV, heart rate and HRV are similar to pre-race values. Finally, our correlation data 
suggests that if a participant performs intermittent moderate intensity bouts throughout 
the race, central arterial stiffness (i.e. PWV) may be lower 24 hours after the race 




 It is recommended that a future study examines the role of exercise intensity on 
non-traditional cardiovascular outcomes such as central blood pressure and arterial 
stiffness. The present study explored the potential influence of exercise intensity on 
central arterial stiffness (i.e. PWV) responses to ultramarathon or marathon events. 
Figure 6A below demonstrates a consistent vigorous intensity (> 6 METs) during a 50 
mile run for one participant, while Figure 6B demonstrates an intermittent intensities 
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strategy with a higher percentage of race time performing moderate intensity activity (i.e. 
3 to 6 METs). Our preliminary results suggest that a higher percentage of time at 
moderate intensity may result in more favorable (i.e. reduced) PWV outcomes. Thus, 
runners might choose to go out and enjoy an ultramarathon with some intermittent 
moderate intensity for health benefits, rather than having a performance outcome and 
performing consistent vigorous activity. The influencing of intensity on markers of acute 






Figure 6. Continuous (A) and intermittent (B) intensity variations (blue line = 3 METs 
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APPENDIX A – Informed Consent Form 
Acute Effects of the Marquette 50 and Marquette Marathon on 
Cardiovascular Health    
Bridget E. Durocher1, John J. Durocher, Ph.D.2 and Scott Drum, Ph.D.1  
1Department of Health, Physical Education and Recreation 
Northern Michigan University 
Marquette, MI 49855 
Phone: (906) 227-2195 
 2Department of Biological Sciences 
Michigan Technological University 
Houghton, MI 49931 
Phone: (906) 487-1659 
Fax: (906) 487-3167 
Email: bduroche@nmu.edu, jjduroch@mtu.edu or sdrum@nmu.edu 
 
Introduction 
We are writing to invite you to participate in a research study starting one or two days 
before the Marquette Trail Ultra-Marathon Race on August 17, 2013 in Marquette, MI 
and / or one or two days before the Marquette Marathon on August 31, 2013. The 
purpose of this study is to analyze your activity / sleep patterns starting 24 to 48 hours 
preceding the race and up to 15 days post-race with an ActiCal accelerometer (worn on 
the wrist), and arterial stiffness and blood C-reactive protein concentration once about 
24 to 48 hours preceding the race and again 24 hours post-race. 
 
M.S. student Bridget Durocher, Dr. John Durocher, Dr. Scott Drum and 
graduate/undergraduate research students will undertake this research study. Dr. 
Durocher and Dr. Drum are assistant professors in their respective departments listed 
above. Neither are medical doctors, nor will the experiment be supervised by a medical 
doctor. The purpose of this study is to determine the effect of marathon and ultra-
marathon running on measures of arterial stiffness (i.e. a non-invasive estimate of how 
well your arteries stretch) and on C-reactive protein concentration (i.e. estimate of 
general inflammation via small finger poke blood sample). This study will also quantify 
your activity levels during the race and your sleep habits on the days surrounding the 
race with a very light (16 gram) wrist accelerometer. 
 
You will be excluded from the proposed research study if you: 
- Smoke  
- Are diabetic or have ever suffered from a stroke or heart attack 
- Take any heart/blood pressure medications or have a pacemaker  
- Are pregnant or on hormone replacement therapy 
- Weigh less than 110 pounds 
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- Have had caffeine, alcohol, or regular exercise in the 12 hours preceding 
laboratory testing 
- Have not fasted for at least 3 hours prior to laboratory testing 
- Have a resting blood pressure >140/90 mmHg and / or a central pulse pressure > 
50 mmHg during the pre-race screening 
 
Experimental Protocol: 
If you agree to participate, we would like to collect information on you before, during, and 
after the Marquette Trail Ultra-Marathon Race and / or the Marquette Marathon Race, 
this data will include: 
1) Activity / sleep patterns starting the day before the race until at least 24 hours 
post-race via ActiCal accelerometer. The small wrist watch-like devices can 
indicate energy expenditure, exercise intensity and sleep time. 
 
2) Participant data including height, weight, body fat (via impedance scale), resting 
blood pressure, C-reactive protein concentration (you will have an ~50 µL finger 
poke blood sample taken by a trained investigator for this measurement), brief 
cardiovascular history for men and women, and menstrual cycle information from 
women. 
 
3) Heart rate variability testing for a 5 minute resting supine baseline with a 3-
lead electrocardiogram. Two surface electrodes will be placed near the sternum 
and one near the lower rib cage to record electrical activity of the heart. 
 
4) Arterial stiffness will be recorded 24-48 hours before the race as a baseline 
measurement and then about 24 hours post-race with a non-invasive tonometer. 
This is a very small probe that simply needs to be held over the desired pulse 
site for 10 seconds. Two consecutive recordings of 10 seconds will be taken at 
each pulse site (i.e. radial, carotid and femoral). 
 
5) You are required to report to the Exercise Science Laboratory on the first floor of 
the Physical Education Instructional Facility at Northern Michigan University for 
an orientation session to become familiar with the experimental protocol and 
equipment 24-48 hours before the scheduled race begins. We will answer any 
questions that you have at this meeting, and then proceed with pre-race 
measurements. You will also be required to report back to the same laboratory 
24 hours after you complete the race for post-race measurements and at one 
more scheduled time to return your ActiCal accelerometer.  
 
6) The following summarizes the experimental protocol to be performed at each 




Set-up / Download ActiCal Accelerometer   10 minutes 
Record Descriptive Data (height, weight, bodyfat, etc.) 5 minutes 
Finger Poke Blood Sample 5 minutes 
Placing of Surface Electrodes and Marking Pulse Sites 10 minutes 
Heart Rate Variability Testing    5 minutes 
Tonometry Testing        10minutes                                           




We do not guarantee that you will derive personal benefits from this study. However, the 
pre-race laboratory test results (i.e. resting blood pressure >140/90 mmHg when 
averaged from two automated cuff readings and / or a central pulse pressure > 50 
mmHg when averaged from two tonometry readings) could indicate you have an 
elevated risk for adverse cardiovascular events, such as a heart attack. If you have an 
abnormal reading on either of the two variables mentioned above, we will verbalize our 
results to you and provide written information explaining the increased health risks, 
including the suggestion that you should discuss the results with your physician; 
however, because we are not medical doctors and unable to diagnose adverse 
cardiovascular events, we cannot mandate that you don’t run the race. However, you 
would be excluded from the current study if your resting blood pressure or estimated 
central pulse pressure exceed the limits above. We recognize that you understand the 
inherent risks of running an endurance event (based on you signing a race waiver form 
explaining said risks), including the possibility of inducing a heart attack or other adverse 
event, such as severe dehydration or muscle cramps. Finally, your participation may 
benefit others by enabling scientists to learn more about the effects of long-distance 
running races on the cardiovascular system, including how blood pressure and/or arterial 
stiffness change from pre- to post-race.  
Compensation 
You will be provided a $20 gift card to Doncker’s in Marquette, MI for your participation.  
Risks, Inconveniences, Discomforts 
Electrocardiogram: Local skin reactions may occur in susceptible individuals. This is 
extremely unusual, but we can stop the experiment if this irritation occurs. To date, we 
have never had a problem with our electrodes. There is no other known risk.  
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Actigraphy: There are no known risks associated with actigraphy. Skin irritation could 
potentially arise around the wrist band used to secure the accelerometer to the 
participant.  
Finger Poke Blood Sample: There is a very small risk of infection. To combat this, 
sterile techniques will be used, and an experienced investigator will perform the 
procedure in the Exercise Science Laboratory. All of the supplies used for this procedure 
are for single use only, thus further preventing the risk of infection. With only a 50 µL 
sample required this should produce minimal discomfort.  
Applanation Tonometry: This is a non-invasive procedure that is comparable to 
someone checking your radial, carotid or femoral pulse via finger palpation. There is no 
known risk of undergoing the procedure; however, as stated prior, you may learn of an 
abnormal reading and how this may increase the chance of a cardiovascular event 
during exercise. 
Impedance Analysis of Body Fat (Tanita BC-418): A very low voltage, high frequency, 
electrical current will pass through your body from the hand and feet electrodes, but you 
will not be able to detect the current. This current passes very easily though water-rich 
muscle, but is resistant to flow through water-poor fat. Thus the extent of resistance to 
this high frequency current is used to indicate body fat (i.e. high resistance indicating 
higher fat). There are no known risks; the manufacturer only recommends that those 
with pacemakers should not use the device and that testing should not occur during 
menstruation (for accuracy) in women. 
Cost of Participation  
There will be no cost to you for participating in this research.  
Research Related Injury 
In the event of physical and/or mental injury resulting from participation in this research 
project, Northern Michigan University and Michigan Technological University do not 
provide any medical, hospitalization or other insurance for participants in this research 
study, nor will Northern Michigan University or Michigan Technological University 
provide any medical treatment or compensation for any injury sustained as a result of 
participation in this research study, except as required by law. If you are taking 
medications, it is your responsibility to consult with your physician regarding your 
participation in this research study. Do not volunteer for this study if you have been 
instructed to abstain from this research study by a physician. Any problems you 
experience throughout this study should be discussed immediately with your physician. 
Confidentiality of Records 
We will treat your identity with professional standards of confidentiality. The information 
obtained in this study may be published, but your identity will not be revealed. Paper files 
containing your subject information sheets and corresponding six digit code will be 
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stored in a secured file cabinet in Dr. Drum’s office or Dr. Durocher’s research laboratory 
(Dow 521). Northern Michigan University and Michigan Technological University reserve 
the right to inspect both the research data collected and your experimental records. 
 
Withdrawal 
Participation in this study is voluntary. Bridget Durocher, Dr. Drum or Dr. Durocher will 
answer any questions you may have about the study. Any significant new findings which 
develop during the course of the research study which in our opinion may affect your 
willingness to continue to participate will be provided to you as soon as possible. You 
are free to withdraw your consent and discontinue participation at any time and 
for any reason. This includes the right to withdraw during the actual test. If you 
withdraw yourself during the actual testing, you will still be compensated for that session.  
Subject's Rights Information  
The NMU and MTU Institutional Review Boards have reviewed my request to conduct 
this project.  If you have any further questions regarding your rights as a participant in a 
research project you may contact Dr. Brian Cherry of the Human Subjects Research 
Review Committee of Northern Michigan University (906-227-2300) bcherry@nmu.edu. 
Any questions you have regarding the nature of this research project will be answered 
by the principal researcher who can be contacted as follows: Dr. Scott Drum (906-227-
2195 office or 970-371-2620 cell) sdrum@nmu.edu.  You may also contact the MTU-IRB 
at 906-487-2902 or email irb@mtu.edu.    
Review Board Approval Number:_______   
 
I, _______________________, have read through this consent form. The investigator 
provided me an opportunity to ask questions and I wish to voluntarily participate in this 
study. 
 
__________________________________________         ______ 
Signature of Subject                                Date 
 
__________________________________________        ______ 
Signature of Investigator                              Date 




APPENDIX B – Email to Participants 
 
Hello, 
You are receiving this e-mail because you are registered for the Marquette Ultramarathon 
and have expressed interest in participating in a research study about the event.  In 
response to your inquiry, you should have received from us an informed consent 
document describing the study procedures, benefits, and potential risks in detail.  We are 
contacting you to confirm your interest in the study, and also to schedule pre and post-
race testing times with you. 
Pre-race and post-race testing will each take between 45 minutes and one hour to 
complete.   Pre-race testing may be completed at your convenience on Thursday, August 
15
th
 or Friday, August 16
th
.  Post-race testing will be completed on Sunday, August 18
th
, 
and should be completed as near as possible to 24-hours after you finish the race.  If you 
are still interested in participating, please respond with the following information to aid 
us in scheduling pre- and post-race testing times: 
1. Your desired pre-race testing date (August 15th or 16th) and time. 
2. Your expected race completion time.   We will use this to help build a tentative 
post-race testing schedule, and will confirm an actual post-race testing 
appointment with you based on your actual race completion time. 
Please note that although we prefer to conduct your post-race test as near as possible to 
24-hours after you complete the event, your appointment can be adjusted slightly to 
accommodate travel or other scheduling conflicts. 








APPENDIX C – Outline of Testing Schedule 
Marquette Ultramarathon / Marathon Study 




1. All resting BP & HR measurements will be recorded as the average of two 
measurements separated by one minute.  Each of these two measurements must 
differ by ≤ 10.0 mm/Hg for DBP and SBP, and by ≤ 10.0 bpm for HR.  If this is 
not the case, additional measurements will be taken (each separated by one 
minute) until two consecutive measurements meet these criteria. 
2. Pulse sites that need to be marked: radial, femoral, carotid. 
3. Criteria for central pulse pressure: must be ≤ 50 mm/Hg.  Greater than 50 mm/Hg 
for two consecutive readings will exclude participants from the study. 
4. Electrode placement sites: White – inferior to the suprasternal notch; Red – 
xyphoid process; Black – just below 10
th
 rib @ left midaxillary line. 
 
  
 Seated Resting BP & HR 
1
  Supine Resting BP & HR
1
 


























 Radial x2 
 Carotid x 2 
 Femoral x2 
      
 0:00 10:00 15:00 20:00 30:00 35:00      45:00 
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APPENDIX D – Participant Descriptive Data 
 
Pre-Race Data: 
Age (yr) Height (cm) Weight (kg) BMI (kg/m
2
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APPENDIX E – Resting Cardiovascular and Metabolic Data 
 
Pre-Race Data: 
RHR (bpm) SAP DAP MAP [CRP] mg/L 
55 119 75 89 1.5 
52 126 59 82 0.5 
60 135 63 87 0.4 
41 131 72 92 0.5 
69 137 72 94 0.5 
66 146 81 102 0.5 
50 108 64 78 0.6 
53 123 76 92 0.3 
70 131 86 101 0.4 
52 144 88 106 0.3 
40 108 60 76 0.3 




RHR (bpm) SAP DAP MAP [CRP] mg/L 
54 116 64 81 1.7 
57 126 47 73 10.0 
50 123 61 82 6.2 
54 125 58 80 10.0 
64 126 56 79 10.0 
60 135 62 86 10.0 
48 104 60 75 9.4 
46 110 76 87 2.6 
76 114 72 86 7.4 
54 144 90 108 1.8 
46 104 54 71 . 








Time (hr:min:sec) EE (kcal) % Light % Mod % Vig 
80 km 12:48:16 7522 4.56 29.43 65.89 
80 km 12:44:43 7900 0.79 25.16 74.04 
80 km 11:04:26 5543 1.05 38.55 60.39 
80 km 10:50:32 8297 0.46 11.83 87.71 
80 km 12:48:11 7573 4.69 34.51 60.81 
50 km 6:28:24 3740 0.26 31.70 68.04 
50 km 6:14:51 4454 0.27 7.73 92.00 
50 km 5:59:40 3143 0.28 11.11 88.61 
42 km 4:07:58 2653 0.81 0.40 98.79 
42 km 3:47:41 3147 0.88 0.44 98.68 
42 km 3:22:21 2197 0.99 0.50 98.51 
42 km 4:55:37 3370 0.68 3.38 95.95 
* Participant number 1 was the only participant that recorded sedentary activity (i.e. 1 to 





APPENDIX G – Means, Standard Deviations and Standard Errors for Major Variables 
 
 Variable Race N Mean SD SE 
Weight (kg) Pre 12 65.7 8.8 2.5 
 Post 12 65.3 8.8 2.5 
Bodyfat (%) Pre 10 14.1 3.6 1.2 
 Post 10 12.7 3.6 1.1 
HR (BPM) Pre 12 55.1 9.8 2.8 
 Post 12 56.1 9.0 2.6 
SAP (mmHg) Pre 12 128.5 12.3 3.6 
 Post 12 121.3 12.1 3.5 
DAP (mmHg) Pre 12 73.5 9.9 2.8 
 Post 12 64.7 11.4 3.1 
MAP (mmHg) Pre 12 99.4 9.5 3.0 
 Post 12 89.7 9.6 2.8 
[CRP] (mg/L) Pre 11 0.5 0.3 0.1 
 Post 11 7.0 3.4 1.0 
HRV (LF:HF) Pre 12 1.8 1.8 0.5 
 Post 12 1.3 0.8 0.2 
aSAP (mmHg) Pre 12 111.2 11.1 3.2 
 Post 12 101.5 11.2 3.2 
aDAP (mmHg) Pre 12 73.2 9.6 2.8 
 Post 12 63.5 11.3 3.3 
aMAP (mmHg) Pre 12 89.0 11.3 3.3 
 Post 12 79.7 12.0 3.5 
aPP (mmHg) Pre 12 38.0 5.2 1.5 
 Post 12 37.7 7.3 2.1 
AIx (%) Pre 12 12.8 13.8 4.0 
 Post 12 5.9 11.9 3.4 
 
 
